Seattle Genetics

Seattle Genetics? Not anymore. The biotech has shortened its name to Seagen to illustrate global expansion
Endpoints
Thu, 10/8/20 - 11:23 pm
Seattle Genetics
Seagen
name change
expansion
Why Seattle Genetics Stock Jumped 24% in September
Motley Fool
Wed, 10/7/20 - 10:44 am
Seattle Genetics
Merck
oncology
Tukysa
Seattle Genetics stays step ahead of rivals with bladder cancer data
BioPharma Dive
Sat, 09/19/20 - 09:04 pm
Seattle Genetics
Astellas
Padcev
bladder cancer
clinical trials
ESMO
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Biopharma Reporter
Mon, 09/14/20 - 10:58 am
Merck
Seattle Genetics
cancer
oncology
ADCs
Tukysa
ladiratuzumab vedotin
Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off
EP Vantage
Tue, 06/30/20 - 10:34 am
cervical cancer
tisotumab vedotin
Genmab
Seattle Genetics
clinical trials
Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water
Fierce Pharma
Tue, 05/5/20 - 12:47 pm
Seattle Genetics
Padcev
bladder cancer
FDA approves first new drug under Project Orbis
RAPS.org
Fri, 04/17/20 - 08:42 pm
FDA
Seattle Genetics
Tukysa
advanced HER2-positive breast cancer
breast cancer
Project Orbis
How a Seattle Genetics cancer drug could help lupus patients with kidney damage
Fierce Biotech
Thu, 04/9/20 - 10:35 am
Seattle Genetics
lupus
kidney damage
PX-478
Seattle Genetics Issue Update on Padcev Label Expansion Study
Yahoo/Zacks.com
Sat, 04/4/20 - 11:21 pm
Seattle Genetics
Padcev
Merck
Keytruda
urothelial cancer
Seattle could waltz in where Astra failed
EP Vantage
Fri, 03/6/20 - 10:34 am
AstraZeneca
Imfinizi
bladder cancer
Seattle Genetics
clinical trials
Padcev
Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Fierce Pharma
Fri, 02/14/20 - 05:07 pm
Astellas
Seattle Genetics
Padcev
advanced bladder cancer
bladder cancer
Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
Motley Fool
Thu, 02/13/20 - 11:29 pm
Seattle Genetics
tucatinib
FDA
priority review
breast cancer
HER-2 postive breast cancer
Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response
Reuters
Tue, 02/11/20 - 10:46 am
Seattle Genetics
Astellas
bladder cancer
Padcev
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
BioSpace
Mon, 02/10/20 - 10:19 am
earnings
Bristol-Myers Squibb
AbbVie
Novo Nordisk
Merck
GSK
Seattle Genetics
Seattle Genetics Reports Q4 Earnings Results
Motley Fool
Thu, 02/6/20 - 11:40 pm
Seattle Genetics
earnings
Are Biotech Stocks Due for a Correction in 2020?
Motley Fool
Thu, 01/16/20 - 10:08 am
biotech stocks
Axsome Therapeutics
Seattle Genetics
Vertex Pharmaceuticals
3 Blockbuster Cancer Drug Launches to Watch in 2020
Motley Fool
Thu, 01/2/20 - 11:57 pm
FDA
drug approvals
cancer
drug launches
AstraZeneca
Enhertu
Padcev
Seattle Genetics
BeiGene
Brukinsa
Seattle Genetics, Astellas snag quick FDA approval for bladder cancer-fighter Padcev
Fierce Pharma
Wed, 12/18/19 - 11:57 pm
Seattle Genetics
Astellas
FDA
Padcev
metastatic bladder cancer
SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data
Fierce Biotech
Wed, 12/11/19 - 10:27 am
Seattle Genetics
breast cancer
tucatinib
HER2+ breast cancer
SABCS
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
BioSpace
Tue, 12/3/19 - 10:29 pm
Seattle Genetics
Daiichi Sankyo
antibody-drug conjugate

Pages